［1］ KRISTENSEN NP,HEEKE C,TVINGSHOLM SA,et al.Neoantigen-reactive CD8+T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma［J］.J Clin Invest,2022,132(2):e150535.
[2] ZHU C,ZHAO Y,HE J,et al.TIL-derived CAR T cells improve immune cell infiltration and survival in the treatment of CD19-humanized mouse colorectal cancer［J］.Cancers (Basel),2023,15(23):5567.
[3] CHEN C,WANG Z,DING Y,et al.Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma［J］.Front Immunol,2023,14:1133308.
[4] HIRAI I,FUNAKOSHI T,KAMIJUKU H,et al.Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors［J］.Cancer Sci,2021,112(8):3163-3172.
[5] ROSENBERG SA,PACKARD BS,AEBERSOLD PM,et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.A preliminary report［J］.N Engl J Med,1988,319(25):1676-1680.
[6] WU R,HORIMOTO Y,OSHI M,et al.Emerging measurements for tumor-infiltrating lymphocytes in breast cancer［J］.Jpn J Clin Oncol,2024,54(6):620-629.
[7] HUDSON JM,CASTILLEJA A,MURRAY JL,et al.Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer［J］.J Interferon Cytokine Res,1998,18(7):529-536.
[8] CROSSEY F,MARX S,HOLTERS S,et al.Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure［J］.Urol Oncol,2018,36(9):402.e1-402.e10.
[9] ROBBINS PF,LU YC,EL-GAMIL M,et al.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells［J］.Nat Med,2013,19(6):747-752.
[10] GROS A,ROBBINS PF,YAO X,et al.PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors［J］.J Clin Invest,2014,124(5):2246-2259.
[11] SWARTZ AM,REAP E,NORBERG P,et al.A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis［J］.J Immunol Methods,2018,459:90-93.
[12] ANDERSEN R,BORCH TH,DRAGHI A,et al.T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression［J］.Ann Oncol,2018,29(7):1575-1581.
[13] TAVERA RJ,FORGET MA,KIM YU,et al.Utilizing T-cell activation signals 1,2,and 3 for tumor-infiltrating lymphocytes(TIL) expansion:The advantage over the sole use of Interleukin-2 in cutaneous and uveal melanoma［J］.J Immunother,2018,41(9):399-405.
[14] NORBERG SM,HINRICHS CS.Engineered T cell therapy for viral and non-viral epithelial cancers［J］.Cancer Cell,2023,41(1):58-69.
[15] ROHAAN MW,BORCH TH,VAN DEN BERG JH,et al.Tumor-infiltrating lymphocyte therapy or Ipilimumab in advanced melanoma［J］.N Engl J Med,2022,387(23):2113-2125.
[16] BESSER MJ,SHAPIRA-FROMMER R,TREVES AJ,et al.Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients［J］.J Immunother,2009,32(4):415-423.
[17] DONIA M,JUNKER N,ELLEBAEK E,et al.Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution［J］.Scand J Immunol,2012,75(2):157-167.
[18] ROSENBERG SA,YANG JC,SHERRY RM,et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy［J］.Clin Cancer Res,2011,17(13):4550-4557.
[19] KVERNELAND AH,BORCH TH,GRANHOJ J,et al.Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition［J］.Cytotherapy,2021,23(8):724-729.
[20] NGUYEN LT,SAIBIL SD,SOTOV V,et al.Phase Ⅱ clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2［J］.Cancer Immunol Immunother,2019,68(5):773-785.
[21] DUDLEY ME,YANG JC,SHERRY R,et al.Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens［J］.J Clin Oncol,2008,26(32):5233-5239.
[22] TANG T,HUANG X,LU M,et al.Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner［J］.Nat Commun,2023,14(1):3364.
[23] ELLEBAEK E,IVERSEN TZ,JUNKER N,et al.Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients［J］.J Transl Med,2012,10:169.
[24] ROHAAN MW,WILGENHOF S,HAANEN JBAG.Adoptive cellular therapies:the current landscape［J］.Virchows Arch,2019,474(4):449-461.
[25] NIEDERLOVA V,TSYKLAURI O,KOVAR M,et al.IL-2-driven CD8+T cell phenotypes:implications for immunotherapy［J］.Trends Immunol,2023,44(11):890-901.
[26] ANDERSEN R,DONIA M,ELLEBAEK E,et al.Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen［J］.Clin Cancer Res,2016,22(15):3734-3745.
[27] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
[28] ALDUAIS Y,ZHANG H,FAN F,et al.Non-small cell lung cancer (NSCLC):A review of risk factors,diagnosis,and treatment［J］.Medicine (Baltimore),2023,102(8):e32899.
[29] OTANO I,UCERO AC,ZUGAZAGOITIA J,et al.At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC［J］.Nat Rev Clin Oncol,2023,20(3):143-159.
[30] DESAI A,PETERS S.Immunotherapy-based combinations in metastatic NSCLC［J］.Cancer Treat Rev,2023,116:102545.
[31] KRADIN RL,BOYLE LA,PREFFER FI,et al.Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer［J］.Cancer Immunol Immunother,1987,24(1):76-85.
[32] RATTO GB,ZINO P,MIRABELLI S,et al.A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma［J］.Cancer,1996,78(2):244-251.
[33] GENG Y,SHAO Y,HE W,et al.Prognostic role of tumor-infiltrating lymphocytes in lung cancer:a meta-analysis［J］.Cell Physiol Biochem,2015,37(4):1560-1571.
[34] HIRAOKA K,MIYAMOTO M,CHO Y,et al.Concurrent infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small-cell lung carcinoma［J］.Br J Cancer,2006,94(2):275-280.
[35] TAY C,TANAKA A,SAKAGUCHI S.Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy［J］.Cancer Cell,2023,41(3):450-465.
[36] CREELAN BC,WANG C,TEER JK,et al.Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer:a phase 1 trial［J］.Nat Med,2021,27(8):1410-1418.
[37] SCHOENFELD A,LEE S，PAZ-ARES L，et al.First phase 2 results of autologous tumor-infiltrating lymphocyte(TIL;LN-145) monotherapy in patients with advanced,immune checkpoint inhibitor-treated,non-small cell lung cancer(NSCLC)［J］.Immunother Cancer,2021,9:A1-A1054.
[38] TENG MWL,NGIOW SF,RIBAS A,et al.Classifying cancers based on T-cell infiltration and PD-L1［J］.Cancer Res,2015,75(11):2139-2145.
[39] SUN D,LIU J,ZHOU H,et al.Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC［J］.J Thorac Oncol,2023,18(7):869-881.
[40] KAZEMI MH,SADRI M,NAJAFI A,et al.Tumor-infiltrating lymphocytes for treatment of solid tumors:It takes two to tango［J］.Front Immunol,2022,13:1018962.
[41] ZHAO Y,DENG J,RAO S,et al.Tumor infiltrating lymphocyte(TIL) therapy for solid tumor treatment:Progressions and challenges［J］.Cancers(Basel),2022,14(17):4160.
[42] HARATANI K,NAKAMURA A,MAMESAYA N,et al.Tumor microenvironment landscape of NSCLC reveals resistance mechanisms for programmed death-ligand 1 blockade after chemoradiotherapy:A multicenter prospective biomarker study(WJOG11518L:SUBMARINE)［J］.J Thorac Oncol,2023,18(10):1334-1350.
[43] ALDEA M,ANDRE F,MARABELLE A,et al.Overcoming resistance to tumor-targeted and immune-targeted therapies［J］.Cancer Discov,2021,11(4):874-899.
[44] KORNEPATI AVR,VADLAMUDI RK,CURIEL TJ.Programmed death ligand 1 signals in cancer cells［J］.Nat Rev Cancer,2022,22(3):174-189.
[45] CAUSHI JX,ZHANG J,JI Z,et al.Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers［J］.Nature,2021,596(7870):126-132.
[46] CHAMBERLAIN CA,BENNETT EP,KVERNELAND AH,et al.Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy［J］.Mol Ther Oncolytics,2022,24:417-428.